From 14 December 2020 through 31 May 2022 (persons 18–39 years) and 20 August 2022 (persons 5–17 years), 320 potential cases of myocarditis/pericarditis were identified 1 to 98 days after 6 992 340 vaccine doses as part of primary series COVID-19 vaccination, with 224 (70%) verified. Of these, 137 (61%) occurred 0 to 7 days after vaccination; 18 were after the first dose (of 3 562 311 doses administered) and 119 were after the second dose (of 3 430 029 doses administered).
In all age groups, incidence per million doses 0 to 7 days after vaccination was numerically higher in male than in female persons and after dose 2, although confidence intervals were wide and overlapped across sex for some age groups. Incidence was highest for male adolescents ages 12 to 15 years and 16 to 17 years following dose 2.
From 24 September 2021 through 20 August 2022, 101 potential cases of myocarditis/pericarditis were identified 1 to 98 days after 1 848 723 first booster doses, with 77 (76%) verified with a median onset of 4.5 days after vaccination; 39 cases (51%) were verified in the first week versus 38 during the subsequent 13 weeks.
In all age groups, incidence 0 to 7 days after first booster was higher for male compared to female persons, with adolescent males having the highest incidence in 16- to 17-year-olds and in 12- to 15-year-olds. In adults for whom both vaccine products were available, post-booster incidence was higher in male than in female adults and higher in males aged 18 to 29 compared to males aged 30 to 39.
‘We’d been quite careful for most of the pandemic, wearing masks and avoiding many big events. But I was pretty confident that, if I did get it, I would be fine because I’d had my jabs. But I couldn’t get out of bed for days and it took almost a month for me to fully recover.’
Two weeks ago the Centers for Disease Control and Prevention (CDC) published data about the effectiveness of boosters against COVID-19
The CDC failed to publish a tranche of their data, however – omitting the impact on those aged 18-49, who are least likely to benefit from boosters
The CDC are also being criticized for failing to publish their information about child hospitalization rates and comorbidities
A spokeswoman for the CDC said they were concerned that the data would be misinterpreted, pointing out that it was incomplete and not verified
Critics said that it was always better to publish the information rather than withhold, and allow scientists to analyze and explain what they could
It is more than a rebuke to Medley and the modellers though. This pandemic began, for many, with an announcement from Imperial College, whose study predicted 500,000 deaths if we did nothing. We locked down and never tested the prediction.
This time, in the face of what the public saw as dire predictions, we didn’t lock down and the apocalypse never came. The unspoken — and sometimes spoken — implication is clear: are we all fools?
Up to 3.5million Covid vaccine doses are set to be binned after reaching their expiry date, it was revealed today.
A leaked memo last month revealed that tens of millions of jabs sent to hospitals, GP surgeries and pharmacies in the run up to Christmas to fight Omicron had largely went unused.
Now NHS sources say more than half of the doses sent to some clinics are still ‘sitting in fridges’ amid falling demand for the booster shots.
One well-placed official estimated up to 3.5m doses are likely to be binned, based on stock counts in several English regions, the Health Service Journal reports.
Two doses of Pfizer vaccine offer limited protection, says Albert Bourla, Pfizer CEO.
Covid should now be treated as an endemic virus similar to flu, and ministers should end mass-vaccination after the booster campaign, the former chairman of the UK’s vaccine taskforce has said.
With health chiefs and senior Tories also lobbying for a post-pandemic plan for a straining NHS, Dr Clive Dix called for a major rethink of the UK’s Covid strategy, in effect reversing the approach of the last two years and returning to a “new normality”.
“We need to analyse whether we use the current booster campaign to ensure the vulnerable are protected, if this is seen to be necessary,” he said. “Mass population-based vaccination in the UK should now end.”
A leading Australian pharmacist says measures such as wearing masks and getting six-monthly Covid-19 vaccinations could be a reality for many years.
Trent Twomey, National President of the Pharmacy Guild, says if modelling shows that its best for people to get a Covid jab ‘every six months’, then Australians should do so.
He dismissed concerns over lingering vaccine hesitancy and wearing masks, saying Australians ‘just need to accept’ necessary measures because ‘it’s pretty simple’.
Dec 10 (Reuters) – Most of the 43 COVID-19 cases caused by the Omicron variant identified in the United States so far were in people who were fully vaccinated, and a third of them had received a booster dose, according to a U.S. report published on Friday.
The U.S. Centers for Disease Control and Prevention (CDC) said that of the 43 cases attributed to Omicron variant, 34 people had been fully vaccinated. Fourteen of them had also received a booster, although five of those cases occurred less than 14 days after the additional shot before full protection kicks in.
While the numbers are very small, they add to growing concerns that current COVID-19 vaccines may offer less protection against the highly transmissible new variant.
Millions of over-75s in England will miss out on routine health checks until April to free up GPs to help with the UK’s anti-Omicron booster drive.
Campaigners accused the Government of breaking its promises to boost face-to-face appointments and slammed the decision as a ‘self defeating exercise’, as over-75s will flood into A&E with their health problems.
The decision to suspend the health checks came from the Joint Committee on Vaccination and Immunisation (JCVI) in response to the Government’s mammoth effort to turbocharge the UK’s Covid booster to ward off Omicron.
The five most vaccinated states in the United States—Vermont, Rhode Island, Maine, Connecticut and Massachusetts—are all experiencing surges in new COVID-19 cases, as the Biden administration urges people over 50 to get their booster jabs.
Vermont, which is the most vaccinated state, with 73 percent of its population fully jabbed, saw an 18 percent rise in new daily COVID cases over the last 14 days before November 24, according to New York Times data.
On Thursday, the government published its 44th vaccine surveillance report and in a table on page 18 it noted 2,032 deaths of double-vaccinated individuals over 70. More than 3,000 from the same double-jabbed cohort were hospitalised.
Researchers who scoured the records of nearly 800,000 U.S. veterans found that in early March, just as the Delta variant was gaining a toehold across American communities, the three vaccines were roughly equal in their ability to prevent infections.
But over the next six months, that changed dramatically.
By the end of September, Moderna’s two-dose COVID-19 vaccine, measured as 89% effective in March, was only 58% effective.
Some parents are now questioning if Israel moved too fast in jabbing their children. And several health professionals and politicians are demanding the abolition of a policy expected to go into effect next month, which states that the Green Pass will be given only to those who receive a third dose of the vaccine six months after getting a second vaccination.
Professor Sucharit Bhakdi: “You are now witnessing the greatest crime that England has ever committed in its history.”
Vaccines typically do not outperform natural immunity, so it should come as no surprise that Covid vaccines do not offer long-term protection against infection. At the same time, we can be confident that they will continue to work well to prevent severe clinical outcomes. The role of these vaccines is to offer protection to the clinically vulnerable; to foist them upon those who are at negligible risk in the hope of augmenting herd immunity is illogical…
Will boosters achieve what two doses could not? For those who are extremely vulnerable and show no evidence of mounting a significant immune response after two doses, it is entirely reasonable to attempt a third dose.
But it can be to no-one else’s individual gain to submit to a third jab, having already reduced the risk of severe disease (which was very small in the first place for most) by receiving two inoculations. For there to be the collective benefit of herd immunity, the booster would have to provide life-long protection against infection – unless we are willing to accept repeated mass vaccination into the foreseeable future. Aside from being a colossal diversion of limited resources, that would open the door to a permanent state of lockdown as we lurch from one booster campaign to the next.
The real-world study includes data on positive Covid PCR test results between May and July 2021 among more than a million people who had received two doses of Pfizer or AstraZeneca vaccine.
Protection after two shots of Pfizer decreased from 88% at one month to 74% at five to six months.
For AstraZeneca, the fall was from 77% to 67% at four to five months.
I reiterate our call: “slow down and get the science right—there is no legitimate reason to hurry to grant a license to a coronavirus vaccine.”
FDA should be demanding that the companies complete the two year follow-up, as originally planned (even without a placebo group, much can still be learned about safety). They should demand adequate, controlled studies using patient outcomes in the now substantial population of people who have recovered from covid. And regulators should bolster public trust by helping ensure that everyone can access the underlying data.
SARS-CoV-2 spike antigen-specific IgG and IgA elicited by infection mediate viral neutralization and are likely an important component of natural immunity, however, limited information exists on vaccine induced responses. We measured COVID-19 mRNA vaccine induced IgG and IgA in serum serially, up to 145 days post vaccination in 4 subjects. Spike antigen-specific IgG levels rose exponentially and plateaued 21 days after the initial vaccine dose. After the second vaccine dose IgG levels increased further, reaching a maximum approximately 7–10 days later, and remained elevated (average of 58% peak levels) during the additional >100 day follow up period. COVID-19 mRNA vaccination elicited spike antigen-specific IgA with similar kinetics of induction and time to peak levels, but more rapid decline in serum levels following both the 1st and 2nd vaccine doses (<18% peak levels within 100 days of the 2nd shot). The data demonstrate COVID-19 mRNA vaccines effectively induce spike antigen specific IgG and IgA and highlight marked differences in their persistence in serum.